Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 501 to 510 of 1090 total matches.
Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?
The Medical Letter on Drugs and Therapeutics • Sep 05, 2011 (Issue 1372)
C (risk cannot be
ruled out) for use during pregnancy.
DRUG INTERACTIONS — Ticagrelor ...
The FDA has approved ticagrelor (Brilinta –
AstraZeneca), an oral antiplatelet drug, for use with
low-dose aspirin to reduce the rate of thrombotic cardiovascular
events in patients with acute coronary syndrome
(ACS). It will compete with clopidogrel (Plavix)
and prasugrel (Effient) for such use. Clopidogrel is
expected to become available generically in the US
within the next few months.
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2013 (Issue 1418)
product. PML has not been reported with
Tecfidera.5
DRUG INTERACTIONS — Dimethyl fumarate ...
The FDA has approved dimethyl fumarate (Tecfidera –
Biogen Idec), formerly called BG-12, for treatment of
relapsing forms of multiple sclerosis (MS). It is the
third oral drug to be approved in recent years for this
indication.
Valbenazine (Ingrezza) for Tardive Dyskinesia
The Medical Letter on Drugs and Therapeutics • May 22, 2017 (Issue 1521)
excluded from clinical trials.
DRUG INTERACTIONS – Valbenazine is metabolized
by CYP3A4/5 and its active ...
The FDA has approved valbenazine (Ingrezza –
Neurocrine Biosciences), a vesicular monoamine
transporter 2 (VMAT2) inhibitor, for treatment of
tardive dyskinesia in adults. It is the first drug to
be approved in the US for this indication; two other
VMAT2 inhibitors, tetrabenazine (Xenazine, and
generics) and deutetrabenazine (Austedo), were
approved earlier for treatment of chorea associated
with Huntington's disease.
Oral Fingolimod (Gilenya) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010 (Issue 1353)
The Medical Letter®
On Drugs and Therapeutics
Volume 52 (Issues 1353/1354)
December 13/27, 2010 ...
The FDA has approved the marketing of fingolimod
(Gilenya – Novartis) to reduce the frequency of clinical
exacerbations and delay the accumulation of physical
disability in patients with relapsing forms of multiple
sclerosis (MS). Fingolimod is the first oral drug
approved for this indication.
Nizatidine (Axid)
The Medical Letter on Drugs and Therapeutics • Aug 12, 1988 (Issue 772)
of Adverse
Drug Interactions, 1987, p 42, 104; U Klotz et al, J Clin Pharmacol, 27:210, 1987; U Klotz, Scand ...
Nizatidine (Axid - Lilly), a new H2-receptor antagonist similar to cimetidine (Tagamet), ranitidine (Zantac) and famotidine (Pepcid), was recently approved by the US Food and Drug Administration for treatment of active duodenal ulcer and for maintenance therapy after healing. Cimetidine, ranitidine and famotidine are also approved for treatment of pathological hypersecretory conditions such as Zollinger- Ellison syndrome; cimetidine is approved in addition for treatment of gastric ulcers.
Repaglinide for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • May 22, 1998 (Issue 1027)
% with
repaglinide compared to 3% with glyburide and glipizide. No clinically significant drug interactions ...
Repaglinide (Prandin - Novo Nordisk) is a new oral glucose-lowering agent for treating type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus or NIDDM). It has been approved by the FDA for monotherapy or for use in combination with metformin.
Eletriptan (Relpax) for Migraine
The Medical Letter on Drugs and Therapeutics • Apr 28, 2003 (Issue 1155)
, and in pregnancy.
DRUG INTERACTIONS — Serum concentrations of eletriptan increase when CYP3A4 inhibitors are taken ...
Eletriptan hydrobromide (Relpax Pfizer) is now available in the US for oral treatment of migraine headache in adults. It is the seventh serotonin 5-HT1B/1D-receptor agonist (triptan) to be approved by the FDA for this indication. This review describes the pharmacokinetics, adverse effects, drug interactions and recommended dosage of eletriptan. Clinical trials comparing the new drug to placebo and to sumatriptan are presented. A dosage and cost table for all the triptans available in the US is also included. The review concludes with an overall assessment of eletriptan's efficacy and...
Lopinavir/Ritonavir: A Protease-inhibitor Combination
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001 (Issue 1095)
of a pharmacokinetic interaction between the drugs. Lopinavir is metabolized by hepatic P450 CYP3A.
Ritonavir ...
Lopinavir/ritonavir is the first fixed-dose combination of protease inhibitors approved by the FDA for the treatment of HIV infection. It is being marketed for use with other drugs in adults and children more than six months old. Lopinavir is a new drug available only in this combination. Ritonavir is often used with other protease inhibitors to raise their plasma concentrations.
Intravenous Acetaminophen (Ofirmev)
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011 (Issue 1361)
. Pharmaceutical drug overdose. Treat Guidel Med Lett 2006;
4:61.
9. Addendum: warfarin-acetaminophen interaction ...
The FDA has approved an intravenous (IV) formulation
of acetaminophen (Ofirmev – Cadence) for use in
patients ≥2 years old for management of pain either as
monotherapy (mild to moderate pain) or with an opioid
(moderate to severe pain) and for reduction of fever.
Alogliptin (Nesina) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 27, 2013 (Issue 1417)
of bladder cancer has been
reported with long-term use of pioglitazone.
DRUG INTERACTIONS — Alogliptin ...
The FDA has approved the dipeptidyl peptidase-4
(DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment
of type 2 diabetes. In addition to the single-ingredient
product, the FDA also approved fixed-dose
combinations of alogliptin/metformin (Kazano) and
alogliptin/pioglitazone (Oseni) for the same indication.
Alogliptin is the fourth DPP-4 inhibitor to become available
in the US. The other three – saxagliptin (Onglyza),
sitagliptin (Januvia), and linagliptin (Tradjenta) – are also
available in fixed-dose combinations with metformin.